10.26.22 -- Clinical Trials In APAC: Challenges And Opportunities

How can a randomization and trial supply management approach to track and trace help improve its efficiency and efficacy? Find out the answer in this white paper.

In this webinar, learn about the importance of choosing the right imaging modality for clinical trials of neuromuscular disorders.

Preparing for the next era of clinical development and therapy commercialization, companies must choose: move forward with innovations spurred by the pandemic, or retrench into default practices.

This article covers what the “patient experience” is in clinical trials, the problems with the patient experience in clinical trials, and four ways digital connections can create a positive patient experience in clinical trials.

The shift to DCTs has numerous advantages. But how can the common pitfalls that come with DCTs be avoided?

At IQVIA, we recognize that the proof of a new technology’s useability occurs when we get past pilots and into production. An example of an in-production capability enhanced by artificial intelligence and used by over 6,000 employees across the globe in multiple languages today is our Intelligent eTMF application.

The demand for connected devices in clinical trials has grown significantly, driven by a need for better, more varied data, and renewed bids to improve the patient experience and reduce the burden for trial sites.

Find out how the Digital Medicine Society (DiMe), an interdisciplinary professional society for digital medicine, was able to deploy an eConsent module in less than two weeks to support its remote study to assess nocturnal scratching as an endpoint for patients.

In this e-book, explore the perspective on five of the most significant aspects of early planning to help biotechs bring new treatments to the patients who need them.

In this white paper, gain insight into how the Asia Pacific region, with its rapid growth of clinical trials, presents a great opportunity for conducting clinical research and has become the preferred destination for DCTs.

Clinical trials can expose both predicted and unexpected safety signals. Surveillance must therefore look beyond expected adverse events to detect possible safety signals.

The central goal of decentralized clinical trials is to ease the patient burden and maximize participation — and innovations in digital platforms and technology offer an entirely new level of empowerment and engagement in implementing a decentralized trial.

Janet Williams, senior director, global supply chain management, and Julie Hoffman, senior director of commercial strategy and execution, discuss why ancillaries are as essential as IMPs, and why sponsors should devote as much attention to early planning for ancillary supplies as they do for study drugs.

Manufacturers with aging facilities and technology are certainly in danger of being found by inspectors to not meet the requirement to remain “current” under cGMPs.

This paper highlights why the industry is moving toward RBQM and how sponsors can build a scalable approach that protects trial participants, upholds study integrity, and increases operational efficiencies.